Jeffrey S. Abrams - Concepedia

Author

Jeffrey S. Abrams

Also Known As

Abrams, Jeffrey, Abrams, Jeffrey S., J Abrams, J S Abrams, J. Abrams, J. S. Abrams, J.S. Abrams, Jeffrey Abrams, Jeffrey S Abrams, Jeffrey S. Abrams

183

Publications

13.7K

Citations

H-Index

110

Concepts

All Affiliations

National Cancer Institute University of Maryland, Baltimore National Institutes of Health Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

About

Jeffrey S. Abrams is an author at National Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.3K
2	Health Sciences	8	8	334
3	Engineering	3	3	312
4	Arts	1	1	314
5	Natural Sciences	1	1	19

Jeffrey S. Abrams

Publications

10.5K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer Joseph A. Sparano, Robert J. Gray, Della Makower, New England Journal of Medicine	2018	2.3K
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 Marc L. Citron, Donald A. Berry, Constance Cirrincione, Journal of Clinical Oncology	2003	1.6K
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 Paul E. Goss, James N. Ingle, Silvana Martino, JNCI Journal of the National Cancer Institute	2005	1.1K
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, New England Journal of Medicine	2019	532
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials Edward L. Trimble, Jeffrey S. Abrams, Otis W. Brawley, Journal of Clinical Oncology	2002	526
A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer Paul E. Goss, James N. Ingle, Silvana Martino, Obstetrical & Gynecological Survey Breast OncologyGynecologyPharmacotherapyEarly-stage Breast CancerPaul E.	2004	314
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Journal of Clinical Oncology	2020	281
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 Roy S. Herbst, David R. Gandara, Fred R. Hirsch, Clinical Cancer Research EngineeringBiomarker-driven ProtocolAdvanced Lung DiseaseLung Master ProtocolPathology	2015	232
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design Keith T. Flaherty, Robert J. Gray, Alice P. Chen, JNCI Journal of the National Cancer Institute	2020	221
Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen Paul E. Goss, James N. Ingle, Joseph L. Pater, Journal of Clinical Oncology	2008	191

Page 1